A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2017

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia.
Epistemonikos ID: 3603c86a4660c0a9decbff61f874f73044c634c8
First added on: May 20, 2024